Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma Who Are at Risk for Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant (ASCT)

Next Previous
Search
Trial Profile

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma Who Are at Risk for Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant (ASCT)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Registrational
  • Acronyms PATH
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 10 Dec 2013 Final results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 15 Jul 2013 This trial is recruiting in Belgium, France, United Kingdom and discontinued in Spain, Italy as reported by European Clinical Trials Database record.
    • 31 May 2012 Planned End Date changed from 1 Mar 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top